Vertex Pharmaceuticals · 1 month ago
Vertex Summer Intern 2026, Formulation Development
Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation. They are seeking a motivated intern to join the Formulation Development group, where the intern will work on developing small-molecule formulations and processes to bring transformative medicines to patients.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Review scientific literature
Plan and execute experiments within a cross-functional team
Record and analyze data
Summarize and present results orally and in written reports to stakeholders
Comply with all relevant, ethical, safety, and training procedures
Qualification
Required
Enrolled in an undergraduate or graduate degree program and majoring in Chemistry, Pharmaceutical Sciences, Engineering, or a related scientific field
Previous hands-on laboratory experience
Detail-oriented and organized
Excellent written and oral communication and critical thinking skills
Legal authorization to work in the United States, now and in the future. Please note that Vertex does not provide sponsorship for internships or entry level roles within this part of the organization
You must be available to work full-time, 40 hours per week from May – August 2026
Benefits
Free 24/7 onsite gym access and free access to group exercise classes
Subsidized commuter benefits- transit and parking
Provided meals—free breakfast daily!
Career development opportunities and events, including C Suite engagement
Social events—both intern-only and company-wide
Location-specific perks and extras!
Recognition of National Intern Day
Medical, dental and vision benefits
Generous paid time off (including a week-long company shutdown in the Summer and the Winter)
Educational assistance programs including student loan repayment
A generous commuting subsidy
Matching charitable donations
401(k)
Company
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Funding
Current Stage
Public CompanyTotal Funding
$657.31MKey Investors
Janssen Belgium
2024-07-10Post Ipo Secondary· $1.11M
2022-05-17Post Ipo Equity· $50M
2009-12-03Post Ipo Equity· $443M
Leadership Team
Recent News
2026-01-16
Pharmaceutical Technology
2026-01-15
2026-01-13
Company data provided by crunchbase